Search | Clinical Trials Finder

Conditions: Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma, ARID1A Gene Mutation
Interventions: Bevacizumab, Niraparib; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Charlottesville, Virginia

Conditions: Breast Cancer
Interventions: Capecitabine, Bevacizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: bevacizumab; Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 3
States / cities: Tucson, Arizona • Stanford, California • Houston, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: Nivolumab, Bevacizumab, Pemetrexed, Best Supportive Care, nab-Paclitaxel, Paclitaxel, Docetaxel, Gemcitabine, Erlotinib, Crizotinib, Carboplatin; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 133
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 117 more

Conditions: Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma
Interventions: Bevacizumab, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Retifanlimab; Biological · Procedure · Other + 1 more
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
Interventions: Gevokizumab, Bevacizumab, Modified FOLFOX6, FOLFIRI, Ramucirumab, Paclitaxel, Cabozantinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: Los Angeles, California • St Louis, Missouri • Nashville, Tennessee

Conditions: Ovarian Cancer
Interventions: Ipatasertib, Cobimetinib, Trastuzumab Emtansine, Atezolizumab, Bevacizumab, Paclitaxel, Giredestrant, Abemaciclib, Inavolisib, Palbociclib, Letrozole, Olaparib, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, Cyclophosphamide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 8
States / cities: San Francisco, California • St Louis, Missouri • Charlotte, North Carolina + 5 more

Conditions: Prostate Cancer
Interventions: Docetaxel, Bevacizumab, ADT, Bicalutamide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: Cancer
Interventions: 5-FU, Atezolizumab, Bevacizumab, Carboplatin, Leucovorin, Nab-paclitaxel, Oxaliplatin, Paclitaxel, Pemetrexed; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 11
States / cities: Aurora, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more

Conditions: Breast Cancer
Interventions: Adriamycin and Cytoxan (AC), ABI-007, Taxol, Bevacizumab, pegfilgrastim; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 27
States / cities: Birmingham, Alabama • Sedona, Arizona • Denver, Colorado + 23 more

Conditions: Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions: bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced Solid Tumor
Interventions: BG-C9074, Tislelizumab, Bevacizumab; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Los Angeles, California • Aurora, Colorado • Orlando, Florida + 2 more

Conditions: Endometrial Cancer
Interventions: Carboplatin, Paclitaxel, bevacizumab; Drug
Lead sponsor: David O'Malley; Other
Eligibility: 18 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: MEGF0444A, bevacizumab, carboplatin, paclitaxel, placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 20
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Santa Monica, California + 17 more

Conditions: Stomach Cancer, Gastric (Stomach) Cancer, Neoplasm of Cardioesophageal Junction, Gastrointestinal Stromal Tumor (GIST)
Interventions: bevacizumab, carboplatin, capecitabine; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: BIBF 1120; Drug
Lead sponsor: AA Secord; Other
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: Durham, North Carolina • Charlottesville, Virginia • Norfolk, Virginia

Conditions: Recurrent Glioblastoma Multiforme, Malignant Glioma, Adult Brain Tumor
Interventions: Vorinostat, Bevacizumab; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Neuroblastoma, Sarcoma
Interventions: Cyclophosphamide, Topotecan, and Bevacizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 21 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 6
States / cities: Phoenix, Arizona • Denver, Colorado • Orlando, Florida + 3 more

Conditions: Ovarian Cancer
Interventions: ABBV-901, Bevacizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Denver, Colorado • Chicago, Illinois • San Antonio, Texas + 2 more

Conditions: Metastatic Esophageal, Gastric Cancer, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic HPV Related Solid Tumors, Metastatic Ovarian Carcinoma, Metastatic Soft Tissue Sarcoma, Metastatic Uveal Melanoma
Interventions: LVGN3616 + LVGN6051 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide, LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer
Interventions: bevacizumab, gemcitabine hydrochloride, pemetrexed disodium; Biological · Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Detroit, Michigan

Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
Interventions: Atezolizumab, Bevacizumab, Biospecimen Collection, Carboplatin, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Positron Emission Tomography; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 172
States / cities: Little Rock, Arkansas • Dublin, California • Emeryville, California + 135 more

Conditions: Metastatic Breast Cancer
Interventions: Bevacizumab [Avastin], Paclitaxel, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 66
States / cities: Birmingham, Alabama • Tucson, Arizona • Corona, California + 58 more

Search by objective public record fields.

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model

Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma

Bevacizumab in Treating Patients With Myelodysplastic Syndrome

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients

Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer